<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation (&#34;Journey&#34; or the &#34;Company&#34;) (NASDAQ: DERM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Journey and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 25, 2026, Journey reported its financial results and provided a corporate update. During the Company's disclosures and related analyst questioning, management indicated that prescription demand for Emrosi was exceeding reported revenue, driven in part by reimbursement timing dynamics and the use of co-pay assistance programs. During the call, Journey's management further acknowledged that &#34;a portion of the scripts were not being reimbursed and therefore, hit our co-pay assistance program,&#34; while also stating that gross-to-net performance remained &#34;within line and expectation&#34; and that the demand-to-revenue dynamic was &#34;progressing as expected.&#34; On this news, Journey's stock price fell $2.05 per share, or 30.01%, to close at $4.78 per share on March 26, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDMwJk5ld3NJdGVtSWQ9REM0ODgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MzAyMjQwUFJfTkVXU19VU1BSX19fX19EQzQ4ODAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDMwJk5ld3NJdGVtSWQ9REM0ODgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MzAyMjQwUFJfTkVXU19VU1BSX19fX19EQzQ4ODAy"/></div> </div></div>

DERM

ARKG

Pomerantz Law Firm is investigating claims on behalf of investors of Journey Medical Corporation (NASDAQ: DERM) regarding potential securities fraud or unlawful business practices by the company and its officers. Following a corporate update on March 25, 2026, where management acknowledged issues with prescription reimbursements, Journey's stock price fell by 30.01% to $4.78 per share. Investors are encouraged to contact Pomerantz for more information about joining the class action.

prnewswire

Journey Medical

Ark Genomic Revolution ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

VG Health

iShares Biotechnology ETF

Direxion S&P Biotech Bear 3X

iShares US Pharma

iShares Global Healthcare

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

22:40 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM